What's The BUZZ?

Market News, Products, Services, and Trends

Advertisement

Why 340B Matters: A Response to PhRMA’s Middleman Narrative

Why 340B Matters: A Response to PhRMA’s Middleman Narrative

In recent weeks, PhRMA has amplified a new messaging campaign, including ads and videos such as

“End Middlemen Markups. Put American Patients First.”

These pieces argue that intermediaries in the drug supply chain are driving up costs and suggest that hospitals and safety-net providers may be contributing to the problem.

It’s a compelling narrative, simple, emotional, and easy to digest.
However, it overlooks crucial facts about how drug pricing operates, what drives patient costs, and the vital role of the 340B Drug Pricing Program in supporting vulnerable communities. Read More >

Virtue 340B

Virtue 340B News & Announcements

Virtue 340B provides independent 340B risk oversight for hospitals and health systems operating in an increasingly complex and scrutinized program environment. Rather than managing programs or selling technology, Virtue delivers objective, independent analysis that helps leadership understand where hidden exposure may exist, what that exposure could mean operationally or financially, and whether current oversight would stand up under external scrutiny. Our work translates complex 340B operational realities into clear, defensible insights that executives can act on with confidence.
Through independent audits, mock HRSA audit simulations, and continuous compliance monitoring, Virtue helps organizations detect operational drift early, strengthen oversight structures, and maintain durable, audit-ready programs. By focusing on prevention, visibility, and governance, not just technical compliance, Virtue 340B equips leadership teams with the clarity they need to protect their organizations and confidently defend how their 340B programs are being managed.

RXinsider Staff

Posted by: RXinsider Staff

RXinsider is a multimedia publishing and technology company offering print publications, digital platforms, events, and content creation services to the B2B pharmacy market.

SUBSCRIBE

Name
Subscription Choices
Checkboxes

Request information from Why 340B Matters: A Response to PhRMA’s Middleman Narrative

Name
Address
Subscribe